Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results

Colorectal cancer is one of the most common cancers in the world. Due to its still undetermined pathogenesis, we are searching for signaling pathways that are important in the development of colorectal cancer. In this article, we present results of study on the role of ADAM proteins in colorectal cancer. The study included 85 adult colorectal cancer patients (48 men, 37 women) and 25 patients in the control group (after diagnostic colonoscopy—without cancer). During hospitalization, a serum sample (3 cm3) was collected from the study and control group, anthropometric measurements were conducted and others clinical data were analyzed. In the serum ADAM10, 12, 17, and 28, protein concentrations were determined and, in the next step, examined the relationship between ADAMs concentrations and selected clinical parameters in both groups. The analysis showed that serum levels of ADAM10 and ADAM28 are significantly higher in patients with colorectal cancer and correlate with histopathological grading and with presence of distant metastases. Moreover, noticed the trend to correlate concentrations of adamalysines with higher BMI score. One of the functions of adamalysines is the activation of growth factors involved in cancer, including IGF and TNFα. The increased activity of adamalysines in patients may play a role in the pathogenesis of colorectal cancer. Our study highlights the prevalence of metabolic disorders in the group of patients with diagnosed CRC, and this cancer seems to be a further complication of obesity.

Download Full-text

The role of oophorectomy for colon cancer with ovarian metastasis

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e15113 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e15113-e15113

Author(s):

S. Lee ◽

J. Lee ◽

H. Ahn ◽

J. Park ◽

J. Kim ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Performance Status ◽

Poor Performance ◽

Ovarian Metastasis ◽

Control Group ◽

Poor Performance Status ◽

Ovarian Metastases ◽

Colorectal Cancer Patients

e15113 Background: A recent study demonstrated that colorectal cancer with ovarian metastases were less responsive to chemotherapy compared to extraovarian metastases. Hence, the ovary may actually represent a “sanctuary” for metastatic cells from CRC. The aim of the study was to investigate the impact of oophorectomy on survival of colorectal cancer patients with ovarian metastasis. Methods: Between 1996 and 2008, 83 colorectal cancer patients underwent oophorectomy. For the historical control, 47 colorectal cancer patients without oophorectomy were included in the analysis. Survival and its associated factors were analyzed using Kaplan-Meier method, log-rank test and Cox-regression analysis. Results: The median age was younger (48 years) in the oophorectomy group when compared to the historical control (54 years) (P =.012). The proportion of synchronous metastasis was higher in the oophorectomy than the control group (57% vs 30%, respectively; P=.003). After a median follow-up duration of 60.8 months (range, 7.4 - 169.7 months), the median OS was significantly longer in the oophorectomy group (28.1 vs 21.2 months, oophorectomy vs non-oophoreectomy; P=.038). For ovary-specific survival (date of ovarian metastasis diagnosis to death), colorectal cancer patients with oophorectomy showed significantly favorable survival than the control group (20.8 vs 10.9 months, respectively; P<.001). At univariate analyses, no oophorectomy (P=.038), bilaterality of ovarian metastasis (P=0.032), the presence of extraovarian metastasis (P<0.001), elevated CEA (p<0.001), poor performance status (p=0.001), no palliative chemotherapy(p=0.001), no primary disease resection(p=0.005) were identified as significantly poor prognostic factors for overall survival. The no oophorectomy, no chemotherapy, extraovarian metastasis, elevated CEA, poor performance status retained statistical significance at multivariate level. (p=0.003, p=0.004, p=0.005, p=0.015, p=0.029, respectively). Conclusions: Based on this retrospective analysis, the oophorectomy significantly prolonged survival in colorectal cancer patients with ovarian metastases. A potential role of oophorectomy in the management of colorectal cancer should be prospectively studied. No significant financial relationships to disclose.

Download Full-text

LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.3_suppl.497 ◽

2014 ◽

Vol 32 (3_suppl) ◽

pp. 497-497 ◽

Cited By ~ 2

Author(s):

Michela Del Prete ◽

Mario Scartozzi ◽

Tiziana Prochilo ◽

Luca Faloppi ◽

Riccardo Giampieri ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Outcome ◽

Cancer Patients ◽

Progression Free Survival ◽

Serum Levels ◽

Roc Curve Analysis ◽

Group A ◽

Group B ◽

Colorectal Cancer Patients

497 Background: Although a demonstrated clinical efficacy, a non negligible proportion of colorectal cancer patients does not seem to benefit from regorafenib and are consequently exposed to unnecessary toxicity. LDH serum levels represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis in many tumour types. In colorectal cancer LDH showed a correlation with treatment outcome for patients receiving antiangiogenetic treatment, thus suggesting a possible interaction with the activity profile of these drugs. We analyzed the role of LDH serum levels in predicting clinical outcome for pre-treated metastatic colorectal cancer patients receiving regorafenib. The final aim was to individuate a potentially reliable and easy to use marker for patients stratification. Methods: 118 colorectal cancer patients treated with regorafenib were available for our analysis. For all patients, LDH values were collected within one month before the procedure and after treatment end. LDH cutoff value was determined by ROC curve analysis, patients were then divided into two groups (A and B, below and above cut-off level respectively). Patients were also classified according to the variation in LDH serum levels pre- and post-treatment (increased patients vs. decreased patients). Results: Patients in group A and B proved homogeneous for all clinical characteristics analyzed. In group A patients median progression free survival (PFS) was 3.18 months, whereas it was 1.87 months in group B patients (p = 0.0018). Median overall survival (OS) was 6.23 months and 3.28 months in group A and B respectively (p = 0.048). Significant differences were not noted among the 2 groups for response rate. All the other clinical variables analyzed failed to show any correlation with patients outcome. Conclusions: Our observations seem to suggest a role of LDH as a marker of clinical outcome in colorectal cancer patients receiving regorafenib. We can then speculate that high LDH patients may not be optimal candidates for regorafenib. After further confirmation in larger trial, these findings may be relevant for a better patients stratification and selection.

Download Full-text

Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: A randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e15002 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e15002-e15002

Author(s):

Rong-xin Zhang ◽

Jun-zhong Lin ◽

Gong Chen ◽

Li-ren LI ◽

Zhen-hai LU ◽

...

Keyword(s):

Colorectal Cancer ◽

Side Effects ◽

Cancer Patients ◽

Surgical Resection ◽

Control Group ◽

Control Groups ◽

Safety And Efficacy ◽

Colorectal Cancer Patients ◽

And Control ◽

Intraoperative Chemotherapy

e15002 Background: The safety and efficacy of intraoperative chemotherapy in colorectal cancer have not yet been extensively investigated. This randomized control trial was designed to compare the safety and efficacy of intraoperative chemotherapy in combination with surgical resection to those of traditional surgical resection alone. Patients and Methods: From January 2011 to January 2016, 696 colorectal cancer patients were enrolled in this study: 341 patients were randomly assigned to the intraoperative plus surgery group to receive intraoperative chemotherapy (portal vein, intraluminal, and intraperitoneal chemotherapy plus surgical resection), whereas 344 patients were randomized to the control group to undergo surgery alone. Eleven patients withdrew consent. Surgical complications and side effects of intraoperative chemotherapy were compared between the two groups. Results: Intraoperative chemotherapy did not increase the rate of surgical complications, and no severe chemotherapy-associated side effects were observed. There were no significant differences in the length of hospital stay (8.31 vs. 7.98 days, P = 0.138), length of surgery (170.4 vs. 167.0 min, P = 0.526), length of antibiotic use (2.28 vs. 2.15 days, P = 0.322), or length of drain usage (6.37 vs. 6.16 days, P = 0.387) between the intraoperative chemotherapy and control groups. Four patients in each of the intraoperative chemotherapy and the control groups experienced anastomotic leakage and underwent a second operation (1.2% vs. 1.2%, P = 0.99). There were no deaths within 90 days after surgery in the chemotherapy group, whereas one patient died in the control group (0% vs. 0.3%, P = 0.99). Intraoperative chemotherapy did not decrease the rate of patients who received postoperative adjuvant chemotherapy between the intraoperative group and control group (29.3% vs. 30.2%, P = 0.795). Conclusions: Intraoperative chemotherapy can be safely performed during colorectal surgery; however, follow-up is necessary for a better assessment of its efficacy. Register Number: NCT01465451. Clinical trial information: NCT01465451.

Download Full-text

Role of tumour- associated neutrophils in tissue material and systemic neutrophil inflammation in colorectal cancer patients

Progress in Health Sciences ◽

10.5604/01.3001.0015.6402 ◽

2021 ◽

Vol 11 (2) ◽

pp. 85-98

Author(s):

K. Jakubowska ◽

M. Koda ◽

W. Kisielewski ◽

K. Lomperta ◽

M. Grudzińska ◽

...

Keyword(s):

Colorectal Cancer ◽

Immune Response ◽

Tumor Growth ◽

Cancer Patients ◽

Distant Metastases ◽

Colorectal Cancer Patients ◽

Cancer Tissues ◽

Tumor Associated Neutrophils ◽

Tissue Material

Colorectal cancer (CRC) is one of the most common malignant cancers worldwide. Immune response is appear to be inseparable component of each part of tumorigenesis. Moreover, several studies have shown that some populations of neutrophils, called tumor-associated neutrophils (TANs) can be also actively involved in the tumor growth, anggenesis and development of the distant metastases in various cancer tissues.

Download Full-text

The Role of Vascular Endothelial Growth Factorin Thrombocytosis in Colorectal Cancer Patients

BioScientia Medicina ◽

10.32539/bsm.v2i2.45 ◽

2018 ◽

Vol 2 (2) ◽

pp. 1-7

Author(s):

Subandrate Subandrate ◽

Dwi Indira Setyorini ◽

Mediarty Mediarty ◽

Irsan Saleh

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Serum Levels ◽

Vascular Endothelial ◽

Research Subjects ◽

Elisa Technique ◽

Average Serum ◽

Colorectal Cancer Patients ◽

Endothelial Growth Factor

Backgorund: Colorectal cancer was included in a group of cancer with various complications. One complication that was often a cause of morbidity and mortality was thrombocytosis. In colorectal cancer, the incidence of thrombocytosis associated with the formation of blood vessels around the tumor or angiogenesis. Factors that played an important role in angiogenesis was vascular endothelial growth factor (VEGF). Methods: This study was an observational analytic research in colorectal cancer patients to determine the correlation levels of platelets and serum VEGF levels. A total of 33 patients with colorectal cancer at the Palembang Mohammad Hoesin Hospital be research subjects to examine the levels of platelets and levels of VEGF. The level of serum VEGF was performed using ELISA technique from SIGMAÂ®. Results: The average level of the patient's platelets was281,090.9Â±105,860.8/mm3. In this study, two patients (6.06%) have thrombocytosis.The average serum levels of VEGF research subjects were 221.2 Â± 152.8 pg/mL.Correlation test of levels of serum VEGF and platelets levels showed the value of p=0.040 (p> 0.05) and r = 0468. Conclusions: Thus, it can be concluded that in this research serum VEGF levels are almost always causes an increase in platelet levels in patients with colorectal cancer.

Download Full-text

The role of hope in patients' use of cancer-related coping strategies

10.32920/ryerson.14657682 ◽

2021 ◽

Author(s):

Jenna J Belanger

Keyword(s):

Colorectal Cancer ◽

Coping Strategies ◽

Cancer Patients ◽

Conceptual Design ◽

Avoidance Coping ◽

Established Relationship ◽

Colorectal Cancer Patients ◽

And Coping ◽

The Relationship

Cancer patient's initial appraisal of the disease (i.e., as a threat, harm, or challenge), as well as their level of hope, has been linked to patients' coping strategies (i.e. approach or avoidance coping). However, it is unclear whether the well-established relationship between primary appraisals and coping in moderated by cancer patients' levels of hope. To determine if hope moderated this realationship, colorectal cancer patients (N=122) completed measures of appraisals and hope following their diagnosis and a measure of coping six-months later. Results indicated that patients appraised cancer as more of a challenge than a threat reported high levels of baseline hope. both challenge appraisals and baseline higher hope predicted approach coming six months later, however, hope did not moderate the relationship between appraisals and coping. This study highlights may of the conceptual, design, and psychometric problems present when measuring appraisals, hope, and coping among cancer patients.

Download Full-text

The role of hope in patients' use of cancer-related coping strategies

10.32920/ryerson.14657682.v1 ◽

2021 ◽

Author(s):

Jenna J Belanger

Keyword(s):

Colorectal Cancer ◽

Coping Strategies ◽

Cancer Patients ◽

Conceptual Design ◽

Avoidance Coping ◽

Established Relationship ◽

Colorectal Cancer Patients ◽

And Coping ◽

The Relationship

Download Full-text

472 Addressing the Quality of Hospital Care of Colorectal Cancer Patients Undergoing Surgery: What Did We Learn from the National Bowel Cancer Audit?

British Journal of Surgery ◽

10.1093/bjs/znab134.558 ◽

2021 ◽

Vol 108 (Supplement_2) ◽

Author(s):

C Li ◽

S Z Y Ooi ◽

T Woo ◽

P H M Chan

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

External Validation ◽

Distant Metastases ◽

Management Plan ◽

Bowel Cancer ◽

Clinical Factors ◽

Quality Outcomes ◽

Colorectal Cancer Patients

Abstract Aim To identify the most relevant clinical factors in the National Bowel Cancer Audit (NBOCA) that contribute to the variation in the quality of care provided in different hospitals for colorectal cancer patients undergoing surgery. Method Data from 36,116 patients with colorectal cancer who had undergone surgery were retrospectively collected from the NBOCA and analysed from 145 and 146 hospitals over two years. A validated multiple linear regression was performed to compare the identified clinical factors with various quality outcomes. The quality outcomes defined in this study were the length of hospitalisation, 2-year mortality, readmission rate, 90-day mortality, and 18-month stoma rate. Results Four clinical factors (laparoscopy rate, abdominal-perineal-resection-of-rectum (APER), pre-operative radiotherapy and patients with distant metastases) were shown to have a significant (p < 0.05) impact on the length of hospitalisation and 18-month stoma rate. 18-month stoma rate was also significantly associated with 2-year mortality. External validation of the regression model demonstrated the Root-Mean-Square-Error of 0.811 and 4.62 for 18-month stoma rate and 2-year mortality respectively. Conclusions Hospitals should monitor the four clinical factors for patients with colorectal cancer during perioperative care. Clinicians should consider these factors along with the individual patients’ history when formulating a management plan for patients with colorectal cancer.

Download Full-text